The estimated Net Worth of Herb Cross is at least $617 ezer dollars as of 2 August 2023. Mr Cross owns over 5,487 units of Atreca Inc stock worth over $6,554 and over the last 17 years he sold BCEL stock worth over $18,823. In addition, he makes $591,574 as Chief Financial Officer at Atreca Inc.
Mr has made over 2 trades of the Atreca Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 5,487 units of BCEL stock worth $5,213 on 2 August 2023.
The largest trade he's ever made was selling 7,646 units of Atreca Inc stock on 2 September 2022 worth over $13,610. On average, Mr trades about 1,010 units every 26 days since 2007. As of 2 August 2023 he still owns at least 72,817 units of Atreca Inc stock.
You can see the complete history of Mr Cross stock trades at the bottom of the page.
Herbert C. Cross is the Chief Financial Officer at Atreca Inc.
As the Chief Financial Officer of Atreca Inc, the total compensation of Mr Cross at Atreca Inc is $591,574. There are 1 executives at Atreca Inc getting paid more, with John A. Orwin having the highest compensation of $863,516.
Mr Cross is 49, he's been the Chief Financial Officer of Atreca Inc since . There are 2 older and 1 younger executives at Atreca Inc. The oldest executive at Atreca Inc is Dr. Tito A. Serafini Ph.D., 58, who is the Founder, Chief Strategy Officer & Director.
Herb's mailing address filed with the SEC is C/O ATRECA, INC., 835 INDUSTRIAL RD., SUITE 400, SAN CARLOS, CA, 94070.
Over the last 5 years, insiders at Atreca Inc have traded over $4,571,843 worth of Atreca Inc stock and bought 6,001 units worth $76,740 . The most active insiders traders include Group, Llc Green Jeremy Red..., Bros. Advisors Lp Baker Bro... és Harbor Master Investors (Ca.... On average, Atreca Inc executives and independent directors trade stock every 20 days with the average trade being worth of $991. The most recent stock trade was executed by John A Orwin on 11 April 2024, trading 1 units of BCEL stock currently worth $0.
atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. with its immune repertoire capture™ (irc™) technology, atreca has an unparalleled insight into how cancer patients’ immune responses can drive better clinical outcomes. atreca was founded by scientists, industry experts, and investors who share the vision that unlocking the immune response of today’s patients is the key to creating a new generation of therapies. atreca is looking for talented, entrepreneurial people who are dedicated to making a positive impact on human health. if you are interested in becoming part of the atreca team, our open positions can be found at: http://www.atreca.com/careers/
Atreca Inc executives and other stock owners filed with the SEC include: